Merck at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

Merck takes part in 2 sessions at ACT 2026 in San Antonio. Its program covers biomarkers of blood vessel injury, part of a look at vascular inflammation. It also evaluates in vitro kidney models to study how megalin-mediated transport contributes to drug-induced kidney injury.

OrganizationACT 2026 Attendance
Merck
Rahway, NJ
◆Gold Supporter
merck.com
Pharmaceutical companiesGold Supporter
US-based global pharmaceutical company, known as MSD outside the US and Canada, making prescription medicines and vaccines.
Talk
Mon Nov 16
10:45am–11:15am
Part of Beyond the Vessel Wall: Translational Insights into Vascular Inflammation (S03)
Biomarkers of Vascular Injury (S03-4)
Bioanalysis and biomarkers
Poster
Mon Nov 16
5:00pm–6:30pm

Explore the full ACT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Antonio. Leave your work email and we’ll be in touch.

Privacy

Download the full ACT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Merck

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction